Literature DB >> 30968585

Polycystic Ovary Syndrome and Insulin Physiology: An Observational Quantitative Serum Proteomics Study in Adolescent, Normal-Weight Females.

Antigoni Manousopoulou1, Nasser M Al-Daghri2, Shaun Sabico2, Diana J Garay-Baquero1, Jie Teng1, Amal Alenad1, Majed S Alokail2, Nikos Athanasopoulos3, Efthymios Deligeoroglou3, George P Chrousos3, Flora Bacopoulou3, Spiros D Garbis1,4,5.   

Abstract

BACKGROUND: Polycystic ovary syndrome (PCOS) is a common endocrine disorder associated with insulin resistance, even in the absence of overweight/obesity. The aim of the present study is to examine the global serum proteomic profile of adolescent, normal-weight females with PCOS in order to gain novel insight in the association of this endocrine disorder with insulin physiology and to identify novel circulating markers that can guide intervention protocols.
METHODS: Non-depleted serum from normal-weight (BMI: 18-23 kg m-2 ), adolescent females (13-21 years old) with PCOS (n = 20) is compared to BMI- and age-matched healthy controls (n = 20) using our 3D quantitative proteomics methodology. Serum samples from study participants are randomly pooled to form four biological replicates of females with PCOS and four of healthy controls (n = 5 per sample pool).
RESULTS: One-hundred and twenty-six proteins are differentially expressed in females with PCOS compared to controls. Gene ontology analysis shows significant enrichment for terms related to inflammatory immune response, metabolism and insulin-like growth factor receptor signaling pathway. Circulating levels of IGF-1 and -2 and IGFBP-2, -3, and -4 are found to be lower in females with PCOS compared to healthy controls.
CONCLUSIONS: The present serum proteomics study provides insight into the pro-inflammatory status and insulin dysregulation in young females with PCOS and identifies potential serological markers that can guide early intervention protocols.
© 2019 The Authors. Proteomics - Clinical Application published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  PCOS; iTRAQ; inflammation; insulin resistance; non-depleted serum; proteomics

Mesh:

Substances:

Year:  2019        PMID: 30968585     DOI: 10.1002/prca.201800184

Source DB:  PubMed          Journal:  Proteomics Clin Appl        ISSN: 1862-8346            Impact factor:   3.494


  5 in total

1.  Proteome analysis of endometrial tissue from patients with PCOS reveals proteins predicted to impact the disease.

Authors:  Mehdi Alikhani; Fatemehsadat Amjadi; Mehdi Mirzaei; Yunqi Wu; Faezeh Shekari; Mahnaz Ashrafi; Mehdi Mehdizadeh; Matthew McKay; Sara Taleahmad; Samaneh Aghajanpour; Vivek Gupta; Hossein Baharvand; Reza Aflatoonian; Ghasem Hosseini Salekdeh
Journal:  Mol Biol Rep       Date:  2020-10-24       Impact factor: 2.316

2.  DIA proteomics analysis through serum profiles reveals the significant proteins as candidate biomarkers in women with PCOS.

Authors:  Ying Yu; Panli Tan; Zhenchao Zhuang; Zhejiong Wang; Linchao Zhu; Ruyi Qiu; Huaxi Xu
Journal:  BMC Med Genomics       Date:  2021-05-09       Impact factor: 3.063

Review 3.  Oxidative Stress and Low-Grade Inflammation in Polycystic Ovary Syndrome: Controversies and New Insights.

Authors:  Antonio Mancini; Carmine Bruno; Edoardo Vergani; Claudia d'Abate; Elena Giacchi; Andrea Silvestrini
Journal:  Int J Mol Sci       Date:  2021-02-07       Impact factor: 5.923

4.  Association Between METS-IR and Prehypertension or Hypertension Among Normoglycemia Subjects in Japan: A Retrospective Study.

Authors:  Kai-Yue Han; Jianing Gu; Zhangsheng Wang; Jie Liu; Su Zou; Chen-Xi Yang; Dan Liu; Yingjia Xu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-18       Impact factor: 5.555

5.  Comprehensive plasma proteomic profiling reveals biomarkers for active tuberculosis.

Authors:  Diana J Garay-Baquero; Cory H White; Naomi F Walker; Marc Tebruegge; Hannah F Schiff; Cesar Ugarte-Gil; Stephen Morris-Jones; Ben G Marshall; Antigoni Manousopoulou; John Adamson; Andres F Vallejo; Magdalena K Bielecka; Robert J Wilkinson; Liku B Tezera; Christopher H Woelk; Spiros D Garbis; Paul Elkington
Journal:  JCI Insight       Date:  2020-09-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.